PRKAR1A
PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.
Overview
Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes genetic literature 0.85, affected pathway 0.83, literature 0.86, genetic association 0.01, somatic mutation 0.85, animal model 0.73). IntOGen calls it a driver in 4 cohorts (2 activating, 2 loss-of-function), covering Adrenocortical Carcinoma, Medulloblastoma, Pilocytic Astrocytoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.
- 1 · What it is
PRKAR1A (cAMP-dependent protein kinase type I-alpha regulatory subunit) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Adrenocortical carcinoma, Thyroid cancer, Renal cell carcinoma and 2 more.
- 2 · What goes wrong in cancer
Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells. Location: Cell membrane (UniProt).
- 3 · How drugs use it
No product in this corpus aims at PRKAR1A yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:9388 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P10644 (protein name, function text, keywords and locations (REST API)); CIViC gene PRKAR1A (1 evidence items, 0 assertions, 1 variants; diseases: Melanotic Neurilemmoma (GraphQL API, CC0)); Open Targets ENSG00000108946 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: renal cell carcinoma 0.52, thyroid cancer 0.54 (GraphQL API, CC0)); IntOGen PRKAR1A (driver in 4 cohorts (Act 2, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signalling in cells. Location: Cell membrane (UniProt). Locus 17q24.2 (HGNC).
- Adrenocortical carcinoma: IntOGen driver in 1 cohort (ACC)
- Thyroid cancer: Open Targets association 0.54 with thyroid cancer (MONDO_0002108)
- Renal cell carcinoma: Open Targets association 0.52 with renal cell carcinoma (MONDO_0005086)
- Medulloblastoma: IntOGen driver in 2 cohorts (MBL)
- Paediatric low-grade glioma: IntOGen driver in 1 cohort (PAST)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Melanotic Neurilemmoma.
Latest papers
topQuery for this target: (TITLE:"PRKAR1A" OR ABSTRACT:"PRKAR1A" OR TITLE:"protein kinase cAMP-dependent type I regulatory subunit alpha" OR ABSTRACT:"protein kinase cAMP-dependent type I regulatory subunit alpha" OR TITLE:"cAMP-dependent protein kinase type I-alpha regulatory subunit" OR ABSTRACT:"cAMP-dependent protein kinase type I-alpha regulatory subunit" OR TITLE:"CNC1" OR ABSTRACT:"CNC1" OR TITLE:"PRKAR1" OR ABSTRACT:"PRKAR1" OR TITLE:"TSE1" OR ABSTRACT:"TSE1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRKAR1A, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetKDM3B
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
- TargetLDB1
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
- TargetTCF4
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
- TargetFAM174B
Shares Paediatric low-grade glioma, Medulloblastoma, IntOGen.
- TargetZNRF3
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
- TargetPAX8
Shares Thyroid cancer, CIViC, Open Targets Platform.
- TargetSTAG2
Shares Thyroid cancer, Renal cell carcinoma, CIViC, IntOGen.
- TargetATRX
Shares Adrenocortical carcinoma, Renal cell carcinoma, CIViC, IntOGen.